In chronic inflammatory processes like rheumatoid arthritis (RA) and cardiovascular diseases (CVD) the role of pteridines and chemokines in the immune response is of great interest. The objectives of the study were to obtain information about an involvement of specific chemokines on the inflammatory process in patients with RA and CVD with activated production of the pteridine neopterin. 113 patients with RA according to American College of Rheumatology criteria including 24.8% suffering from CVD were included in the study (23% male, 77% female). For the assessment of monocyte activation and chemotaxis as well as the proinflammatory influence of chemokines on B-cells and angiogenesis in RA, neopterin and the chemokines CCL2, CXCL13 and CX3CL1 were measured by radio-and enzyme-immunoassays in serum. Neopterin and chemokines were all found in high concentrations. Neopterin significantly correlated with all chemokines: CXCL13 (r s = 0.368; p <0.0001), CX3CL1 (r s = 0.241; p <0.02), CCL2 (r s = 231; p <0.02), demonstrating high neopterin levels in RA patients to have a strong association to the chemokine induced chemotaxis of B-cells (CXCL13) and mononuclear cells (CX3CL1, CCL2). Significantly elevated concentrations of neopterin and CXCL13 were seen in patients with RA plus CVD compared to RA without CVD (p <0.03). The high incidence of cardiovascular diseases in rheumatoid arthritis seems to be associated with enhanced mononuclear (neopterin, CCL2) and B-cell activation (CXCL13), and as a consequence increased immune system activity.
Introduction
Rheumatoid arthritis (RA) is characterized by increased inflammatory processes; accumulation of inflammatory cells at the site of inflammation, such as monocytes/macrophages, T cells, B cells, dendritic cells and natural killer (NK) cells, is a multistep process involving chemokines and chemokine receptors (1) . CX3CL1 (Fractalkine) is an important proinflammatory chemokine in RA characterized by synovial angiogenesis, chemotaxis of monocytes and Bcells, activation of monocytes and T-cells as well as the stimulation of matrix degrading enzymes (matrix metalloproteinases, MMPs) (2) . The chemokine CCL2 (Monocyte chemoattractant protein 1, MCP-1), expressed by monocytes, is able to recruit monocytes, T-cells, NK-cells and basophils to sites of infection and inflammation (3) . CXCL13 (B-cell attracting chemokine 1, BCA-1) is classified as a B lymphocyte chemoattractant, predominantly expressed by monocytes/macrophages, follicular dendritic cells, synovial endothelium cells and fibroblasts. CXCL13 binds CXCR5, which is expressed on circulating mature B cells and a subset of memory CD4 + T cells and is therefore important for recruiting of B and T cells into RA synovium (4) . Chemokines are able to stimulate production of more pro-inflammatory mediators (5) . The pteridine neopterin, another signalling molecule involved in the pathogenesis of various inflammatory diseases (autoimmune diseases, cardiovascular diseases, virus infections, etc.), is an indicator for the activation of cell-mediated immune response. Patients with rheuma-toid arthritis show elevated concentrations of neopterin in serum/plasma and urine and were strongly dependent on stage and activity of RA (6). Nasonov et al. could demonstrate that neopterin concentrations correlate well with the inflammatory activity and intensification of systemic symptoms of RA (7) . Neopterin is synthesized by human monocytes/macrophages and dendritic cells upon stimulation with interferon-γ (IFN-γ) which is produced by activated T-lymphocytes and natural killer cells during immune response. Particularly IFN-γ stimulates the enzyme GTP-cyclohydrolase I (GCH-I) to split guanosine triphosphate (GTP) with producing dihydroneopterintriphosphate and neopterin as a consequence of dephosphorylation and oxidation (8, 9) .
A high incidence of cardiovascular diseases (CVD) in RA is known. Observational studies indicate that CVD mortality is increased by approximately 50% in RA patients compared with general population (10) . Furthermore, it could be verified that patients with coronary artery disease (CAD) have increased neopterin levels which correlated with the CAD activity score (11) (12) (13) . Higher neopterin production is also associated with lower concentrations of antioxidant compounds in patients at risk for atherosclerosis (14) . The amount of neopterin correlates with the release of reactive oxygen species (ROS). As a consequence, neopterin concentrations can be regarded as an indirect estimate of the degree of oxidative stress emerging during cell-mediated immune response (15) .
Neopterin and the group of chemokines are both important messengers in the immune response of inflammatory diseases. It should be demonstrated by the following study if the specified characteristics of neopterin and chemokines in patients with RA can be represented in adequate laboratory measurements and if a concomitant cardiovascular disease has any influence on the levels of neopterin and chemokines in RA.
Methods

Patients
The initial medical examination at the rehabilitation centre/special hospital in Saalfelden included 113 patients (23% male, 77% female) with rheumatoid arthritis (American College of Rheumatology criteria). 24.8% of the RA patients additionally suffered from a CVD, cardiac infarct, bypass, stent, atherosclerosis, etc. The patients were aged between 23 and 82 years, 55.8 years on average.
The study was performed according to the principles of the World Medical Association Declaration of Helsinki (16) . The patients underwent no alteration of their clinically ordered therapies and needed no additional blood taking except the routine ones. Therefore the ethic commission of Salzburg assessed the study to be non obligatory for decision. All patients gave informed consent to the laboratory investigations.
Sample collection and laboratory testing
Venous blood samples for routine check-up in the rehabilitation centre were taken in the morning at admission (day 1-3) of the inpatient rehabilitation stay. After serum separation by centrifugation (10 min, 1.750 x g) serum was partitioned and frozen at -50°C. Radioimmunoassays and enzyme immunoassays used for measurement of neopterin, CX3CL1, CXCL13 and CCL2 are listed in Table 1 .
All chemokine ELISAs were evaluated using a microtiter plate photometer (ANTHOS Elisa Reader 2010) and "ADAP Software, Version 1.6" from Anthos (Labtec Instruments GesmbH, Wals, Austria). A gamma counter (1272 Clinigamma, LKB WALLAC) was used for the quantification of neopterin.
For quality management chemokines as well as neopterin were determined in duplicate. CRP was measured in the course of routine check-up using an automatic analyzer (Cobas Integra 400 plus).
Statistical analysis
Results are expressed as mean ± SEM. For the statistical analysis the programs Sigma Plot version 11 and Microsoft Office 2007 were used. The following statistic methods were applied: descriptive statistic, normality test, non-parametric statistic, Spearman correlation analysis. A p-value of <0.05 was considered as statistically significant. To insure the protection of data privacy only encrypted data records were processed.
Results and Discussion
The average of neopterin concentrations (11.1 ± 0.54 nmol/L, 95 th percentile 24.39) of the RA patients (n = 113; Table. 2) markedly exceeds the generally valid normal limits for healthy subjects which is located at 5.34 ± 0.14 nmol/L and age-adjusted between 19 and 75 years (95 th percentile: 8.7 nmol/L) (17) . Higher concentrations of neopterin in RA agree with former investigations of Nasonov et al., who showed elevated neopterin concentrations in serum in correlation to activity and intensification of systemic symptoms of RA (7). In our study, CRP, as a laboratory marker for inflammatory activity, significantly correlates with neopterin (r s = 0.275; p <0.01). Frick et al. showed that neopterin increases with age (18) , which could also be verified by a significant positive correlation of our data (r s = 0.361; p <0.0001, Table 4 ). A statistical gender analysis of neopterin, chemokines and CRP showed no difference. Furthermore, we found high concentrations of the investigated chemokines CXCL13, CX3CL1 and CCL2 with strong correlations among themselves (Table 4) . Also a correlation between age and CXCL13 respectively CCL2 was observed. Neopterin significantly correlates with all the measured chemokines CX3CL1 (p <0.02), CCL2 (p <0.02) but most significantly with CXCL13 (r s = 0.368, p <0.0001) as shown in Table 4 . This could be verified by separating the RA patients into two groups, first -neopterin levels lower than 9 nmol/L, and second -neopterin levels higher than 9 nmol/L. According to the correlation results it could be demonstrated that in case of elevated neopterin also significantly higher chemokine concentrations are existing (Table 3) .
Monocytes/macrophages, which play an important role as infiltrating cells at the site of inflammation, produce neopterin as well as the investigated chemokines CXCL13, CCL2, and CX3CL1 upon immune activation and stimulation by IFN-γ (19) . Again chemokines are able to recruit and stimulate the infiltrating inflammatory cells to produce IFN-γ which stimulates the monocytes; CX3CL1 activates T-lymphocytes and NK cells, whereas CXCL13 addresses Band slightly T-cell activation (20) . Monocytes are also recruited in a chemotactic way by CCL2 respectively CX3CL1. CX3CL1 mediates T-cell dependent proliferation of synovial fibroblasts in RA (21) . Within the scope of this comprehensive immunological network, neopterin concentrations reflect the activation degree of monocytes/macrophages and other immune cells and consequently the extent and activity of cellular immune activation (22) . Patients with RA are at increased risk for morbidity and mortality from cardiovascular disease (23) . Likewise, 24.8% of our RA patients additionally suffered from CVD. Patients with RA plus CVD (n = 28) compared to RA patients without vascular problems (n = 85) showed significantly higher concentrations of neopterin and CXCL13 (p <0.03, Fig.1 ), CRP (p <0.05), and slightly increased levels of CCL2. This indicates that CVD in rheumatoid arthritis is associated with enhanced mononuclear-(neopterin, CCL2) and B-cell activation (CXCL13), and as a consequence increased immune activity. Rho et al. found higher neopterin concentrations in RA and systemic lupus erythematosus compared to healthy controls associated with erythrocyte sedimentation rate but not associated with coronary atherosclerosis in either disease (24) . Patients with CVD show elevated levels of several inflammatory mediators -in particular elevated neopterin concentrations have been reported in patients with various cardiovascular diseases like coronary disease, reviewed by Fuchs et al. (13) , coronary and peripheral artery disease (12) . Neopterin might predict adverse cardiovascular events in patients with coronary artery disease, acute coronary syndromes or peripheral artery disease and levels of neopterin are related to the development of heart failure (25) . Inflammation, immunologic disturbances, and metabolic changes have to be under good control to minimize cardiovascular risk in RA (23). Table 3 : Chemokines concentrations in patients grouped accorrding to their neopterin concentrations; Group 1 with low neopterin levels <9 nmol/L, Group 2 with high neopterin levels >9 nmol/L). (total n = 113) Mean = arithmetic mean value, S E M = standard error of mean, Median = geometric mean value, p = significance, ns = not significant. 
Conclusion
High neopterin levels in RA patients have strong association to the chemokine induced chemotaxis of B-cells (CXCL13). The high incidence of coronary vascular diseases in rheumatoid arthritis could be associated with enhanced mononuclear (neopterin, CCL2) and B-cell activation (CXCL13), and as a consequence increased immune system activity. Neopterin and chemokines seem to interact in the network of cellular immune response. The activation of immunoactive cells (e.g. activated T-cells and B-cells) by the chemotactic active chemokines stimulates neopterin production in monocytes/macrophages. 
